{
    "EVIDENCE": {
        "id": 262,
        "name": "EID262",
        "description": "A 28 year-old patient with non-small cell lung cancer that failed conventional therapy was found to harbor the EML4-ALK (E13;A20) fusion using reverse transcription PCR. Treatment with 250mg crizotinib twice daily resulted in rapid improvement of symptoms and disease control for 5 months.",
        "disease": {
            "id": 8,
            "name": "Lung Non-small Cell Carcinoma",
            "display_name": "Lung Non-small Cell Carcinoma",
            "doid": "3908",
            "url": "http://www.disease-ontology.org/?id=DOID:3908"
        },
        "drugs": [
            {
                "id": 12,
                "name": "Crizotinib",
                "ncit_id": "C74061",
                "aliases": [
                    "Xalkori",
                    "PF-2341066",
                    "PF-02341066",
                    "MET Tyrosine Kinase Inhibitor PF-02341066",
                    "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                    "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine"
                ]
            }
        ],
        "rating": 4,
        "evidence_level": "C",
        "evidence_type": "Predictive",
        "clinical_significance": "Sensitivity/Response",
        "evidence_direction": "Supports",
        "variant_origin": "Somatic",
        "drug_interaction_type": null,
        "status": "accepted",
        "type": "evidence",
        "source": {
            "id": 166,
            "name": "EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.",
            "citation": "Choi et al., 2010, N. Engl. J. Med.",
            "citation_id": "20979473",
            "source_type": "PubMed",
            "asco_abstract_id": null,
            "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20979473",
            "open_access": null,
            "pmc_id": null,
            "publication_date": {
                "year": 2010,
                "month": 10,
                "day": 28
            },
            "journal": "N. Engl. J. Med.",
            "full_journal_title": "The New England journal of medicine",
            "status": "fully curated",
            "is_review": false,
            "clinical_trials": []
        },
        "variant_id": 5,
        "phenotypes": [],
        "assertions": [
            {
                "id": 3,
                "type": "assertion",
                "name": "AID3",
                "summary": "Lung adenocarcinoma positive for ALK-FUSIONS have been found to be sensitive to crizotinib treatment",
                "description": "ALK-FUSIONS induce an active form of the receptor tyrosine kinase ALK.  ALK-FUSIONS are found in 3-5% of non-small cell lung cancer and act as a targetable driver mutation. the ALK inhibitor crizotinib was effective in lung cancer patients with ALK fusions and was granted accelerated FDA approval in 2011. The Vysis break-apart FISH assay is an FDA approved test for the presence of ALK fusion. NCCN guideline version 9.2017 lists crizotinib as approved first-line NSCLC treatment in the presence of ALK fusions but now lists alectinib as preferred first-line therapy.",
                "gene": {
                    "name": "ALK",
                    "id": 1
                },
                "variant": {
                    "name": "ALK FUSIONS",
                    "id": 499
                },
                "disease": {
                    "id": 8,
                    "name": "Lung Non-small Cell Carcinoma",
                    "display_name": "Lung Non-small Cell Carcinoma",
                    "doid": "3908",
                    "url": "http://www.disease-ontology.org/?id=DOID:3908"
                },
                "drugs": [
                    {
                        "id": 12,
                        "name": "Crizotinib",
                        "ncit_id": "C74061",
                        "aliases": [
                            "Xalkori",
                            "PF-2341066",
                            "PF-02341066",
                            "MET Tyrosine Kinase Inhibitor PF-02341066",
                            "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                            "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine"
                        ]
                    }
                ],
                "evidence_type": "Predictive",
                "evidence_direction": "Supports",
                "clinical_significance": "Sensitivity/Response",
                "fda_regulatory_approval": true,
                "status": "accepted"
            }
        ],
        "gene_id": 1
    },
    "GENE": {
        "id": 1,
        "name": "ALK",
        "entrez_id": 238,
        "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.",
        "variants": [
            {
                "name": "ALK FUSIONS",
                "id": 499,
                "evidence_items": {
                    "accepted_count": 31,
                    "rejected_count": 2,
                    "submitted_count": 10
                }
            },
            {
                "name": "EML6-ALK e1-e20 and FBXO11-ALK e1-e20",
                "id": 2750,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "EML4-ALK e6-e20",
                "id": 503,
                "evidence_items": {
                    "accepted_count": 7,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "EML4-ALK e2-e20",
                "id": 501,
                "evidence_items": {
                    "accepted_count": 2,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "EML4-ALK e20-e20",
                "id": 500,
                "evidence_items": {
                    "accepted_count": 4,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "EML4-ALK e6-e19 G1269A and AMPLIFICATION",
                "id": 3204,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "F1245C",
                "id": 549,
                "evidence_items": {
                    "accepted_count": 2,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "STRN-ALK",
                "id": 2218,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "ALTERNATIVE TRANSCRIPT (ATI)",
                "id": 839,
                "evidence_items": {
                    "accepted_count": 2,
                    "rejected_count": 0,
                    "submitted_count": 2
                }
            },
            {
                "name": "MUTATION",
                "id": 512,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "NPM-ALK",
                "id": 513,
                "evidence_items": {
                    "accepted_count": 3,
                    "rejected_count": 1,
                    "submitted_count": 0
                }
            },
            {
                "name": "RANBP2-ALK",
                "id": 514,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "DEL4-11",
                "id": 550,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "EML4-ALK I1171S",
                "id": 589,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "CLTC-ALK",
                "id": 520,
                "evidence_items": {
                    "accepted_count": 3,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "F1174C",
                "id": 1492,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "L1196Q",
                "id": 1553,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "EML4-ALK",
                "id": 5,
                "evidence_items": {
                    "accepted_count": 7,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "F1174L",
                "id": 8,
                "evidence_items": {
                    "accepted_count": 9,
                    "rejected_count": 0,
                    "submitted_count": 3
                }
            },
            {
                "name": "EML4-ALK L1196M",
                "id": 7,
                "evidence_items": {
                    "accepted_count": 4,
                    "rejected_count": 0,
                    "submitted_count": 11
                }
            },
            {
                "name": "EML4-ALK S1206Y",
                "id": 172,
                "evidence_items": {
                    "accepted_count": 2,
                    "rejected_count": 0,
                    "submitted_count": 2
                }
            },
            {
                "name": "EML4-ALK L1152R",
                "id": 307,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "ALK FUSION G1269A",
                "id": 552,
                "evidence_items": {
                    "accepted_count": 4,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "ALK FUSION G1202R",
                "id": 171,
                "evidence_items": {
                    "accepted_count": 6,
                    "rejected_count": 0,
                    "submitted_count": 3
                }
            },
            {
                "name": "ALK FUSION F1245C",
                "id": 551,
                "evidence_items": {
                    "accepted_count": 3,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "EML4-ALK T1151INST",
                "id": 173,
                "evidence_items": {
                    "accepted_count": 4,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "HIP1-ALK I1171N",
                "id": 588,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 0,
                    "submitted_count": 2
                }
            },
            {
                "name": "ALK FUSION I1171",
                "id": 527,
                "evidence_items": {
                    "accepted_count": 7,
                    "rejected_count": 0,
                    "submitted_count": 3
                }
            },
            {
                "name": "EML4-ALK  V1180L",
                "id": 528,
                "evidence_items": {
                    "accepted_count": 5,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "EML4-ALK G1269A",
                "id": 308,
                "evidence_items": {
                    "accepted_count": 2,
                    "rejected_count": 0,
                    "submitted_count": 6
                }
            },
            {
                "name": "L1198F",
                "id": 1275,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 1,
                    "submitted_count": 1
                }
            },
            {
                "name": "F1174V",
                "id": 1505,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "L1152P",
                "id": 1554,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "L1198P",
                "id": 1556,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "R1192P",
                "id": 1661,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 1,
                    "submitted_count": 2
                }
            },
            {
                "name": "R1275Q",
                "id": 9,
                "evidence_items": {
                    "accepted_count": 6,
                    "rejected_count": 0,
                    "submitted_count": 3
                }
            },
            {
                "name": "F1245V",
                "id": 1295,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 1,
                    "submitted_count": 0
                }
            },
            {
                "name": "OVEREXPRESSION",
                "id": 2635,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "R214H",
                "id": 1683,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "T1151M",
                "id": 1493,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "EXPRESSION",
                "id": 2914,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "ALK FUSION L1196M",
                "id": 2819,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "G1128A",
                "id": 2798,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 1,
                    "submitted_count": 1
                }
            },
            {
                "name": "EML4-ALK G1202del",
                "id": 2813,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "EML4-ALK L1198F",
                "id": 2816,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "EML4-ALK G1202R and L1198F",
                "id": 2811,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "EML4-ALK L1196M and L1198F",
                "id": 2810,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "EML4-ALK G1202R and L1196M",
                "id": 2809,
                "evidence_items": {
                    "accepted_count": 0,
                    "rejected_count": 0,
                    "submitted_count": 2
                }
            },
            {
                "name": "CAD-ALK",
                "id": 2769,
                "evidence_items": {
                    "accepted_count": 1,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "EML4-ALK C1156Y-L1198F",
                "id": 352,
                "evidence_items": {
                    "accepted_count": 2,
                    "rejected_count": 0,
                    "submitted_count": 1
                }
            },
            {
                "name": "EML4-ALK and AMPLIFICATION",
                "id": 170,
                "evidence_items": {
                    "accepted_count": 3,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            },
            {
                "name": "EML4-ALK C1156Y",
                "id": 6,
                "evidence_items": {
                    "accepted_count": 4,
                    "rejected_count": 2,
                    "submitted_count": 7
                }
            }
        ],
        "aliases": [
            "ALK",
            "NBLST3",
            "CD246"
        ],
        "type": "gene"
    },
    "VARIANT": {
        "id": 5,
        "entrez_name": "ALK",
        "entrez_id": 238,
        "name": "EML4-ALK",
        "description": "The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.",
        "gene_id": 1,
        "type": "variant",
        "variant_types": [
            {
                "id": 120,
                "name": "transcript_fusion",
                "display_name": "Transcript Fusion",
                "so_id": "SO:0001886",
                "description": "A feature fusion where the deletion brings together transcript regions.",
                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
            }
        ],
        "civic_actionability_score": 38,
        "coordinates": {
            "chromosome": "2",
            "start": 42396490,
            "stop": 42522656,
            "reference_bases": null,
            "variant_bases": null,
            "representative_transcript": "ENST00000318522.5",
            "chromosome2": "2",
            "start2": 29415640,
            "stop2": 29446394,
            "representative_transcript2": "ENST00000389048.3",
            "ensembl_version": 75,
            "reference_build": "GRCh37"
        },
        "evidence_items": [
            {
                "id": 1121,
                "name": "EID1121",
                "description": "A 39-year-old man presented was observed to have lung acinar adenocarcinoma. Treatment with chemotherapy produced no remarkable response. A EGFR L858R point mutation was observed; the patient was therefore treated with erlotinib, but the disease progressed after 30 days. A second biopsy identified a EML4-ALK fusion, which may explain the therapeutic resistance.",
                "disease": {
                    "id": 1594,
                    "name": "Lung Acinar Adenocarcinoma",
                    "display_name": "Lung Acinar Adenocarcinoma",
                    "doid": "6482",
                    "url": "http://www.disease-ontology.org/?id=DOID:6482"
                },
                "drugs": [
                    {
                        "id": 15,
                        "name": "Erlotinib",
                        "ncit_id": "C65530",
                        "aliases": []
                    }
                ],
                "rating": 2,
                "evidence_level": "C",
                "evidence_type": "Predictive",
                "clinical_significance": "Resistance",
                "evidence_direction": "Supports",
                "variant_origin": "Somatic",
                "drug_interaction_type": null,
                "status": "accepted",
                "type": "evidence",
                "source": {
                    "id": 776,
                    "name": "A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.",
                    "citation": "Tanaka et al., 2012, BMC Cancer",
                    "citation_id": "23181703",
                    "source_type": "PubMed",
                    "asco_abstract_id": null,
                    "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23181703",
                    "open_access": true,
                    "pmc_id": "PMC3515412",
                    "publication_date": {
                        "year": 2012
                    },
                    "journal": "BMC Cancer",
                    "full_journal_title": "BMC cancer",
                    "status": "fully curated",
                    "is_review": false,
                    "clinical_trials": []
                },
                "variant_id": 5,
                "phenotypes": []
            },
            {
                "id": 1188,
                "name": "EID1188",
                "description": "A retroviral cDNA expression library was constructed using a lung adenocarcinoma specimen from a 67 year old NSCLC patient, and transfected into mouse 3T3 fibroblasts which were assessed for transformed foci.  Analysis of clones from one transformed focus yielded a novel fusion. This fusion generated a protein with N-terminal consisting of EML4 exons 1-13 and C-terminal consisting of ALK exons 20-29, which comprise the intracellular kinase domain of ALK. In subsequent experiments using EML4-ALK or altered versions, the transforming potential of EML4-ALK was found to be dependent on a functional ALK kinase activity as well as the EML4 basic domain, which was shown to have an important role in EML4-ALK dimer formation.  BA/F3 cells expressing EML4-ALK were able to grow independently of IL3 addition, but addition of ALK inhibitor WHI-P154 induced cell death and inhibited tyrosine phosphorylation of EML4-ALK. These results indicated that EML4-ALK may be a driver mutation in NSCLC,  and a target for ALK inhibitor treatment.",
                "disease": {
                    "id": 8,
                    "name": "Lung Non-small Cell Carcinoma",
                    "display_name": "Lung Non-small Cell Carcinoma",
                    "doid": "3908",
                    "url": "http://www.disease-ontology.org/?id=DOID:3908"
                },
                "drugs": [
                    {
                        "id": 301,
                        "name": "WHI-P154",
                        "ncit_id": null,
                        "aliases": []
                    }
                ],
                "rating": 5,
                "evidence_level": "D",
                "evidence_type": "Predictive",
                "clinical_significance": "Sensitivity/Response",
                "evidence_direction": "Supports",
                "variant_origin": "Somatic",
                "drug_interaction_type": null,
                "status": "accepted",
                "type": "evidence",
                "source": {
                    "id": 820,
                    "name": "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.",
                    "citation": "Soda et al., 2007, Nature",
                    "citation_id": "17625570",
                    "source_type": "PubMed",
                    "asco_abstract_id": null,
                    "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/17625570",
                    "open_access": null,
                    "pmc_id": null,
                    "publication_date": {
                        "year": 2007,
                        "month": 8,
                        "day": 2
                    },
                    "journal": "Nature",
                    "full_journal_title": "Nature",
                    "status": "fully curated",
                    "is_review": false,
                    "clinical_trials": []
                },
                "variant_id": 5,
                "phenotypes": []
            },
            {
                "id": 1203,
                "name": "EID1203",
                "description": "In preclinical work using H3122 NSCLC cells which contain the EML4-ALK variant 1, administration of the Hsp90 inhibitor IPI-504 caused marked decrease of EML4-ALK protein levels at concentrations lower than those used to knock down protein levels of drivers such as HER2 or EGFR in other cell lines, making it the most sensitive Hsp90 client protein the authors had encountered.  IPI-504 treatment caused regression of H3122 tumors in nude mice, whereas Hsp90 inhibitors usually only cause growth inhibition in these models.  Combined treatment of these mice with IPI-504 and crizotinib caused an even stronger tumor regression.",
                "disease": {
                    "id": 8,
                    "name": "Lung Non-small Cell Carcinoma",
                    "display_name": "Lung Non-small Cell Carcinoma",
                    "doid": "3908",
                    "url": "http://www.disease-ontology.org/?id=DOID:3908"
                },
                "drugs": [
                    {
                        "id": 303,
                        "name": "Retaspimycin Hydrochloride",
                        "ncit_id": "C48401",
                        "aliases": [
                            "IPI-504",
                            "Geldanamycin, 18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)-, Monohydrochloride",
                            "17-Allylamino-17-demethoxygeldanamycin Hydroquinone Hydrochloride"
                        ]
                    },
                    {
                        "id": 12,
                        "name": "Crizotinib",
                        "ncit_id": "C74061",
                        "aliases": [
                            "Xalkori",
                            "PF-2341066",
                            "PF-02341066",
                            "MET Tyrosine Kinase Inhibitor PF-02341066",
                            "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                            "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine"
                        ]
                    }
                ],
                "rating": 4,
                "evidence_level": "D",
                "evidence_type": "Predictive",
                "clinical_significance": "Sensitivity/Response",
                "evidence_direction": "Supports",
                "variant_origin": "Somatic",
                "drug_interaction_type": "Combination",
                "status": "accepted",
                "type": "evidence",
                "source": {
                    "id": 832,
                    "name": "The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.",
                    "citation": "Normant et al., 2011, Oncogene",
                    "citation_id": "21258415",
                    "source_type": "PubMed",
                    "asco_abstract_id": null,
                    "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/21258415",
                    "open_access": null,
                    "pmc_id": null,
                    "publication_date": {
                        "year": 2011,
                        "month": 6,
                        "day": 2
                    },
                    "journal": "Oncogene",
                    "full_journal_title": "Oncogene",
                    "status": "fully curated",
                    "is_review": false,
                    "clinical_trials": []
                },
                "variant_id": 5,
                "phenotypes": []
            },
            {
                "id": 1206,
                "name": "EID1206",
                "description": "Transduction of Ba/F3 cells with EML4-ALK variant 1 causes IL3 independent growth. Incubation of EML4-ALK variant 1 transduced Ba/F3 cells with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation, and that EML4-ALK variant 1 is a client protein of Hsp90. The degree of Hsp90 dependence, and targetability of EML4-ALK for Hsp90 inhibition, may vary among ALK fusion variants.  Addition of crizotinib to 17-DMAG caused synergistic death effects, suggesting potential clinical benefit for this inhibitor combination in targeting EML4-ALK variant 1.",
                "disease": {
                    "id": 8,
                    "name": "Lung Non-small Cell Carcinoma",
                    "display_name": "Lung Non-small Cell Carcinoma",
                    "doid": "3908",
                    "url": "http://www.disease-ontology.org/?id=DOID:3908"
                },
                "drugs": [
                    {
                        "id": 304,
                        "name": "Alvespimycin",
                        "ncit_id": "C38142",
                        "aliases": [
                            "Geldanamycin,17-demethoxy-17-((2-(dimethylamino)ethyl)amino)-",
                            "17-DMAG",
                            "17-dimethylaminoethylamino-17-demethoxygeldanamycin",
                            "17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin"
                        ]
                    },
                    {
                        "id": 12,
                        "name": "Crizotinib",
                        "ncit_id": "C74061",
                        "aliases": [
                            "Xalkori",
                            "PF-2341066",
                            "PF-02341066",
                            "MET Tyrosine Kinase Inhibitor PF-02341066",
                            "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                            "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine"
                        ]
                    }
                ],
                "rating": 2,
                "evidence_level": "D",
                "evidence_type": "Predictive",
                "clinical_significance": "Sensitivity/Response",
                "evidence_direction": "Supports",
                "variant_origin": "Somatic",
                "drug_interaction_type": "Combination",
                "status": "accepted",
                "type": "evidence",
                "source": {
                    "id": 826,
                    "name": "Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.",
                    "citation": "Heuckmann et al., 2012, Clin. Cancer Res.",
                    "citation_id": "22912387",
                    "source_type": "PubMed",
                    "asco_abstract_id": null,
                    "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22912387",
                    "open_access": null,
                    "pmc_id": null,
                    "publication_date": {
                        "year": 2012,
                        "month": 9,
                        "day": 1
                    },
                    "journal": "Clin. Cancer Res.",
                    "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
                    "status": "fully curated",
                    "is_review": false,
                    "clinical_trials": []
                },
                "variant_id": 5,
                "phenotypes": []
            },
            {
                "id": 1207,
                "name": "EID1207",
                "description": "In the PROFILE 1001 study of crizotinib in 82 patients with ALK-rearranged NSCLC, 31 patients with sufficient tumor material were tested using RT-PCR for the presence of certain EML4-ALK variants.  13/31 tested patients had the EML4-ALK variant 1. Of these, 12/13 had a partial response, and 1 had stable disease. This response rate of 92% is in contrast to the 57% response rate in the overall patient population, but the numbers of patients with specific EML4-ALK breakpoints were insufficient to correlate with patient response rate.",
                "disease": {
                    "id": 8,
                    "name": "Lung Non-small Cell Carcinoma",
                    "display_name": "Lung Non-small Cell Carcinoma",
                    "doid": "3908",
                    "url": "http://www.disease-ontology.org/?id=DOID:3908"
                },
                "drugs": [
                    {
                        "id": 12,
                        "name": "Crizotinib",
                        "ncit_id": "C74061",
                        "aliases": [
                            "Xalkori",
                            "PF-2341066",
                            "PF-02341066",
                            "MET Tyrosine Kinase Inhibitor PF-02341066",
                            "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                            "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine"
                        ]
                    }
                ],
                "rating": 4,
                "evidence_level": "C",
                "evidence_type": "Predictive",
                "clinical_significance": "Sensitivity/Response",
                "evidence_direction": "Supports",
                "variant_origin": "Somatic",
                "drug_interaction_type": null,
                "status": "accepted",
                "type": "evidence",
                "source": {
                    "id": 819,
                    "name": "Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.",
                    "citation": "Kwak et al., 2010, N. Engl. J. Med.",
                    "citation_id": "20979469",
                    "source_type": "PubMed",
                    "asco_abstract_id": null,
                    "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20979469",
                    "open_access": true,
                    "pmc_id": "PMC3014291",
                    "publication_date": {
                        "year": 2010,
                        "month": 10,
                        "day": 28
                    },
                    "journal": "N. Engl. J. Med.",
                    "full_journal_title": "The New England journal of medicine",
                    "status": "fully curated",
                    "is_review": false,
                    "clinical_trials": [
                        {
                            "nct_id": "NCT00585195",
                            "name": "A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",
                            "description": "PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.",
                            "clinical_trial_url": "https://clinicaltrials.gov/show/NCT00585195"
                        }
                    ]
                },
                "variant_id": 5,
                "phenotypes": []
            },
            {
                "id": 1332,
                "name": "EID1332",
                "description": "EML4-ALK variant 1 containing H-3122 NSCLC cells were treated with second generation ALK inhibitor PF-06463922. PF-06463922 was 125x more potent at reducing cell viability than crizotinib. Control neuroblastoma cell lines with wild-type ALK did not show inhibition below 3800 nM with either drug. At values of 10 and 100 nM, PF-06463922 showed increased ability to inhibit ALK 1278 tyrosine phosphorylation in H3122 cells.",
                "disease": {
                    "id": 8,
                    "name": "Lung Non-small Cell Carcinoma",
                    "display_name": "Lung Non-small Cell Carcinoma",
                    "doid": "3908",
                    "url": "http://www.disease-ontology.org/?id=DOID:3908"
                },
                "drugs": [
                    {
                        "id": 241,
                        "name": "Lorlatinib",
                        "ncit_id": "C113655",
                        "aliases": [
                            "PF-06463922",
                            "Lorbrena",
                            "7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile",
                            "2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-"
                        ]
                    }
                ],
                "rating": 2,
                "evidence_level": "D",
                "evidence_type": "Predictive",
                "clinical_significance": "Sensitivity/Response",
                "evidence_direction": "Supports",
                "variant_origin": "Somatic",
                "drug_interaction_type": null,
                "status": "accepted",
                "type": "evidence",
                "source": {
                    "id": 919,
                    "name": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "citation": "Infarinato et al., 2016, Cancer Discov",
                    "citation_id": "26554404",
                    "source_type": "PubMed",
                    "asco_abstract_id": null,
                    "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404",
                    "open_access": true,
                    "pmc_id": "PMC4707106",
                    "publication_date": {
                        "year": 2016,
                        "month": 1
                    },
                    "journal": "Cancer Discov",
                    "full_journal_title": "Cancer discovery",
                    "status": "fully curated",
                    "is_review": false,
                    "clinical_trials": []
                },
                "variant_id": 5,
                "phenotypes": []
            },
            {
                "id": 7482,
                "name": "EID7482",
                "description": "One patient with colorectal cancer harboring MSI-High and EML4-ALK rearrangement received Nivolumab and achieved a durable response.",
                "disease": {
                    "id": 11,
                    "name": "Colorectal Cancer",
                    "display_name": "Colorectal Cancer",
                    "doid": "9256",
                    "url": "http://www.disease-ontology.org/?id=DOID:9256"
                },
                "drugs": [
                    {
                        "id": 137,
                        "name": "Nivolumab",
                        "ncit_id": "C68814",
                        "aliases": [
                            "Opdivo",
                            "ONO-4538",
                            "NIVO",
                            "MDX-1106",
                            "BMS-936558"
                        ]
                    }
                ],
                "rating": 3,
                "evidence_level": "C",
                "evidence_type": "Predictive",
                "clinical_significance": "Resistance",
                "evidence_direction": "Does Not Support",
                "variant_origin": "Somatic",
                "drug_interaction_type": null,
                "status": "submitted",
                "type": "evidence",
                "source": {
                    "id": 2971,
                    "name": "ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.",
                    "citation": "Pietrantonio et al., 2017, J. Natl. Cancer Inst.",
                    "citation_id": "29370427",
                    "source_type": "PubMed",
                    "asco_abstract_id": null,
                    "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/29370427",
                    "open_access": null,
                    "pmc_id": null,
                    "publication_date": {
                        "year": 2017,
                        "day": 1
                    },
                    "journal": "J. Natl. Cancer Inst.",
                    "full_journal_title": "Journal of the National Cancer Institute",
                    "status": "fully curated",
                    "is_review": false,
                    "clinical_trials": []
                },
                "variant_id": 5,
                "phenotypes": []
            },
            {
                "id": 262,
                "name": "EID262",
                "description": "A 28 year-old patient with non-small cell lung cancer that failed conventional therapy was found to harbor the EML4-ALK (E13;A20) fusion using reverse transcription PCR. Treatment with 250mg crizotinib twice daily resulted in rapid improvement of symptoms and disease control for 5 months.",
                "disease": {
                    "id": 8,
                    "name": "Lung Non-small Cell Carcinoma",
                    "display_name": "Lung Non-small Cell Carcinoma",
                    "doid": "3908",
                    "url": "http://www.disease-ontology.org/?id=DOID:3908"
                },
                "drugs": [
                    {
                        "id": 12,
                        "name": "Crizotinib",
                        "ncit_id": "C74061",
                        "aliases": [
                            "Xalkori",
                            "PF-2341066",
                            "PF-02341066",
                            "MET Tyrosine Kinase Inhibitor PF-02341066",
                            "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                            "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine"
                        ]
                    }
                ],
                "rating": 4,
                "evidence_level": "C",
                "evidence_type": "Predictive",
                "clinical_significance": "Sensitivity/Response",
                "evidence_direction": "Supports",
                "variant_origin": "Somatic",
                "drug_interaction_type": null,
                "status": "accepted",
                "type": "evidence",
                "source": {
                    "id": 166,
                    "name": "EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.",
                    "citation": "Choi et al., 2010, N. Engl. J. Med.",
                    "citation_id": "20979473",
                    "source_type": "PubMed",
                    "asco_abstract_id": null,
                    "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20979473",
                    "open_access": null,
                    "pmc_id": null,
                    "publication_date": {
                        "year": 2010,
                        "month": 10,
                        "day": 28
                    },
                    "journal": "N. Engl. J. Med.",
                    "full_journal_title": "The New England journal of medicine",
                    "status": "fully curated",
                    "is_review": false,
                    "clinical_trials": []
                },
                "variant_id": 5,
                "phenotypes": []
            }
        ],
        "variant_groups": [
            {
                "id": 11,
                "name": "ALK Fusions",
                "description": "ALK fusion positive non-small cell lung cancer (NSCLC) is treated as its own subset of NSCLC. Many ALK fusions that have been seen as recurrent in cancer serve to increase the activity of the ALK oncogene relative to normal cells. While EML4 is the most common fusion partner, other 5' partners have been observed. The EML4-ALK fusion has shown sensitivity to targeted tyrosine kinase inhibitors such as crizotinib. ",
                "variants": [
                    {
                        "id": 7,
                        "entrez_name": "ALK",
                        "entrez_id": 238,
                        "name": "EML4-ALK L1196M",
                        "description": "In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, L1196M has been shown to confer resistance to crizotinib. This was also true in a patient with both EML4-ALK C1156Y & L1196M.",
                        "gene_id": 1,
                        "type": "variant",
                        "variant_types": [
                            {
                                "id": 47,
                                "name": "missense_variant",
                                "display_name": "Missense Variant",
                                "so_id": "SO:0001583",
                                "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                            },
                            {
                                "id": 120,
                                "name": "transcript_fusion",
                                "display_name": "Transcript Fusion",
                                "so_id": "SO:0001886",
                                "description": "A feature fusion where the deletion brings together transcript regions.",
                                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                            }
                        ],
                        "civic_actionability_score": 21,
                        "coordinates": {
                            "chromosome": "2",
                            "start": 29443631,
                            "stop": 29443631,
                            "reference_bases": "G",
                            "variant_bases": "T",
                            "representative_transcript": "ENST00000389048.3",
                            "chromosome2": null,
                            "start2": null,
                            "stop2": null,
                            "representative_transcript2": null,
                            "ensembl_version": 75,
                            "reference_build": "GRCh37"
                        }
                    },
                    {
                        "id": 499,
                        "entrez_name": "ALK",
                        "entrez_id": 238,
                        "name": "ALK FUSIONS",
                        "description": "Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer. \n\nIn a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response. \n\nDue to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib \u2013 a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.   \n\nALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.",
                        "gene_id": 1,
                        "type": "variant",
                        "variant_types": [
                            {
                                "id": 120,
                                "name": "transcript_fusion",
                                "display_name": "Transcript Fusion",
                                "so_id": "SO:0001886",
                                "description": "A feature fusion where the deletion brings together transcript regions.",
                                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                            }
                        ],
                        "civic_actionability_score": 648,
                        "coordinates": {
                            "chromosome": "2",
                            "start": 29415640,
                            "stop": 29446394,
                            "reference_bases": null,
                            "variant_bases": null,
                            "representative_transcript": "ENST00000389048.3",
                            "chromosome2": null,
                            "start2": null,
                            "stop2": null,
                            "representative_transcript2": null,
                            "ensembl_version": 75,
                            "reference_build": "GRCh37"
                        }
                    },
                    {
                        "id": 6,
                        "entrez_name": "ALK",
                        "entrez_id": 238,
                        "name": "EML4-ALK C1156Y",
                        "description": "In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, C1156Y has been shown to confer resistance to crizotinib. Case reports indicate that secondary mutations can modulate drug sensitivity. EML4-ALK C1156Y/L1196M maintained crizotinib resistance while the lorlatinib resistant combination EML4-ALK C1156Y/L1198F re-sensitized the tumor to crizotinib treatment.",
                        "gene_id": 1,
                        "type": "variant",
                        "variant_types": [
                            {
                                "id": 47,
                                "name": "missense_variant",
                                "display_name": "Missense Variant",
                                "so_id": "SO:0001583",
                                "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                            },
                            {
                                "id": 120,
                                "name": "transcript_fusion",
                                "display_name": "Transcript Fusion",
                                "so_id": "SO:0001886",
                                "description": "A feature fusion where the deletion brings together transcript regions.",
                                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                            }
                        ],
                        "civic_actionability_score": 29,
                        "coordinates": {
                            "chromosome": "2",
                            "start": 29445258,
                            "stop": 29445258,
                            "reference_bases": "C",
                            "variant_bases": "T",
                            "representative_transcript": "ENST00000389048.3",
                            "chromosome2": null,
                            "start2": null,
                            "stop2": null,
                            "representative_transcript2": null,
                            "ensembl_version": 75,
                            "reference_build": "GRCh37"
                        }
                    },
                    {
                        "id": 500,
                        "entrez_name": "ALK",
                        "entrez_id": 238,
                        "name": "EML4-ALK e20-e20",
                        "description": "EML4-ALK variant 2 consists of a fusion of the ALK kinase domain (exons 20-29) with EML4 exons 1-20. Variant 2 has cytoplasmic distribution and makes up ~10% of EML4-ALK fusions found in NSCLC,. Although the specific variant is not consistently reported, single cases demonstrating response to crizotinib treatment in NSCLC and a differentiated malignant neoplasm of unknown origin have been reported. In vitro, this variant has shown greater sensitivity to ALK inhibition with TAE684 and crizotinib than the EML4-ALK variants 1 (E13;A20), 3a (E6;A20) and 3b (E6ins33;A20). The variant was reported to be less stable in cells than other variants, and may be a client protein of Hsp90. Along these lines the variant has shown preclinical sensitivity to Hsp90 inhibition.",
                        "gene_id": 1,
                        "type": "variant",
                        "variant_types": [
                            {
                                "id": 120,
                                "name": "transcript_fusion",
                                "display_name": "Transcript Fusion",
                                "so_id": "SO:0001886",
                                "description": "A feature fusion where the deletion brings together transcript regions.",
                                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                            }
                        ],
                        "civic_actionability_score": 16.5,
                        "coordinates": {
                            "chromosome": "2",
                            "start": 42396490,
                            "stop": 42552694,
                            "reference_bases": null,
                            "variant_bases": null,
                            "representative_transcript": "ENST00000318522.5",
                            "chromosome2": "2",
                            "start2": 29415640,
                            "stop2": 29446394,
                            "representative_transcript2": "ENST00000389048.3",
                            "ensembl_version": 75,
                            "reference_build": "GRCh37"
                        }
                    },
                    {
                        "id": 503,
                        "entrez_name": "ALK",
                        "entrez_id": 238,
                        "name": "EML4-ALK e6-e20",
                        "description": "The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.",
                        "gene_id": 1,
                        "type": "variant",
                        "variant_types": [
                            {
                                "id": 120,
                                "name": "transcript_fusion",
                                "display_name": "Transcript Fusion",
                                "so_id": "SO:0001886",
                                "description": "A feature fusion where the deletion brings together transcript regions.",
                                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                            }
                        ],
                        "civic_actionability_score": 25,
                        "coordinates": {
                            "chromosome": "2",
                            "start": 42396490,
                            "stop": 42491871,
                            "reference_bases": null,
                            "variant_bases": null,
                            "representative_transcript": "ENST00000318522.5",
                            "chromosome2": "2",
                            "start2": 29415640,
                            "stop2": 29446394,
                            "representative_transcript2": "ENST00000389048.3",
                            "ensembl_version": 75,
                            "reference_build": "GRCh37"
                        }
                    },
                    {
                        "id": 501,
                        "entrez_name": "ALK",
                        "entrez_id": 238,
                        "name": "EML4-ALK e2-e20",
                        "description": "",
                        "gene_id": 1,
                        "type": "variant",
                        "variant_types": [
                            {
                                "id": 120,
                                "name": "transcript_fusion",
                                "display_name": "Transcript Fusion",
                                "so_id": "SO:0001886",
                                "description": "A feature fusion where the deletion brings together transcript regions.",
                                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                            }
                        ],
                        "civic_actionability_score": 1.75,
                        "coordinates": {
                            "chromosome": "2",
                            "start": 42396490,
                            "stop": 42472827,
                            "reference_bases": null,
                            "variant_bases": null,
                            "representative_transcript": "ENST00000318522.5",
                            "chromosome2": "2",
                            "start2": 29415640,
                            "stop2": 29446394,
                            "representative_transcript2": "ENST00000389048.3",
                            "ensembl_version": 75,
                            "reference_build": "GRCh37"
                        }
                    },
                    {
                        "id": 520,
                        "entrez_name": "ALK",
                        "entrez_id": 238,
                        "name": "CLTC-ALK",
                        "description": "The t(2;17)(p23;q23) translocation results in the CLTC-ALK fusion protein, the most common ALK fusion observed in diffuse large B cell lymphoma (DLBCL). ALK-rearranged DLBCL is less responsive to CHOP chemotherapy. Preclinical work indicates that CLTC-ALK DLBCL is responsive to ALK inhibition in cell lines and mouse models, and two case studies show short response followed by progression when heavily pretreated and advanced ALK-positive DLBCL is treated with crizotinib (one case CLTC-ALK, one case an unknown ALK fusion).",
                        "gene_id": 1,
                        "type": "variant",
                        "variant_types": [
                            {
                                "id": 120,
                                "name": "transcript_fusion",
                                "display_name": "Transcript Fusion",
                                "so_id": "SO:0001886",
                                "description": "A feature fusion where the deletion brings together transcript regions.",
                                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                            }
                        ],
                        "civic_actionability_score": 19,
                        "coordinates": {
                            "chromosome": "17",
                            "start": 57697219,
                            "stop": 57768072,
                            "reference_bases": null,
                            "variant_bases": null,
                            "representative_transcript": "ENST00000269122.3",
                            "chromosome2": "2",
                            "start2": 29415640,
                            "stop2": 29446394,
                            "representative_transcript2": "ENST00000389048.3",
                            "ensembl_version": 75,
                            "reference_build": "GRCh37"
                        }
                    },
                    {
                        "id": 513,
                        "entrez_name": "ALK",
                        "entrez_id": 238,
                        "name": "NPM-ALK",
                        "description": "",
                        "gene_id": 1,
                        "type": "variant",
                        "variant_types": [
                            {
                                "id": 120,
                                "name": "transcript_fusion",
                                "display_name": "Transcript Fusion",
                                "so_id": "SO:0001886",
                                "description": "A feature fusion where the deletion brings together transcript regions.",
                                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                            }
                        ],
                        "civic_actionability_score": 27,
                        "coordinates": {
                            "chromosome": "5",
                            "start": 170814120,
                            "stop": 170818803,
                            "reference_bases": null,
                            "variant_bases": null,
                            "representative_transcript": "ENST00000517671.1",
                            "chromosome2": "2",
                            "start2": 29415640,
                            "stop2": 29446394,
                            "representative_transcript2": "ENST00000389048.3",
                            "ensembl_version": 75,
                            "reference_build": "GRCh37"
                        }
                    },
                    {
                        "id": 514,
                        "entrez_name": "ALK",
                        "entrez_id": 238,
                        "name": "RANBP2-ALK",
                        "description": "",
                        "gene_id": 1,
                        "type": "variant",
                        "variant_types": [
                            {
                                "id": 120,
                                "name": "transcript_fusion",
                                "display_name": "Transcript Fusion",
                                "so_id": "SO:0001886",
                                "description": "A feature fusion where the deletion brings together transcript regions.",
                                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                            }
                        ],
                        "civic_actionability_score": 10,
                        "coordinates": {
                            "chromosome": "2",
                            "start": 109335937,
                            "stop": 109375004,
                            "reference_bases": null,
                            "variant_bases": null,
                            "representative_transcript": "ENST00000283195.6",
                            "chromosome2": "2",
                            "start2": 29415640,
                            "stop2": 29446394,
                            "representative_transcript2": "ENST00000389048.3",
                            "ensembl_version": 75,
                            "reference_build": "GRCh37"
                        }
                    },
                    {
                        "id": 5,
                        "entrez_name": "ALK",
                        "entrez_id": 238,
                        "name": "EML4-ALK",
                        "description": "The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.",
                        "gene_id": 1,
                        "type": "variant",
                        "variant_types": [
                            {
                                "id": 120,
                                "name": "transcript_fusion",
                                "display_name": "Transcript Fusion",
                                "so_id": "SO:0001886",
                                "description": "A feature fusion where the deletion brings together transcript regions.",
                                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
                            }
                        ],
                        "civic_actionability_score": 38,
                        "coordinates": {
                            "chromosome": "2",
                            "start": 42396490,
                            "stop": 42522656,
                            "reference_bases": null,
                            "variant_bases": null,
                            "representative_transcript": "ENST00000318522.5",
                            "chromosome2": "2",
                            "start2": 29415640,
                            "stop2": 29446394,
                            "representative_transcript2": "ENST00000389048.3",
                            "ensembl_version": 75,
                            "reference_build": "GRCh37"
                        }
                    }
                ],
                "type": "variant_group"
            }
        ],
        "assertions": [],
        "variant_aliases": [],
        "hgvs_expressions": [],
        "clinvar_entries": [
            "N/A"
        ],
        "allele_registry_id": null
    },
    "ASSERTIONS": [
        {
            "id": 3,
            "type": "assertion",
            "name": "AID3",
            "summary": "Lung adenocarcinoma positive for ALK-FUSIONS have been found to be sensitive to crizotinib treatment",
            "description": "ALK-FUSIONS induce an active form of the receptor tyrosine kinase ALK.  ALK-FUSIONS are found in 3-5% of non-small cell lung cancer and act as a targetable driver mutation. the ALK inhibitor crizotinib was effective in lung cancer patients with ALK fusions and was granted accelerated FDA approval in 2011. The Vysis break-apart FISH assay is an FDA approved test for the presence of ALK fusion. NCCN guideline version 9.2017 lists crizotinib as approved first-line NSCLC treatment in the presence of ALK fusions but now lists alectinib as preferred first-line therapy.",
            "gene": {
                "name": "ALK",
                "id": 1
            },
            "variant": {
                "name": "ALK FUSIONS",
                "id": 499
            },
            "disease": {
                "id": 8,
                "name": "Lung Non-small Cell Carcinoma",
                "display_name": "Lung Non-small Cell Carcinoma",
                "doid": "3908",
                "url": "http://www.disease-ontology.org/?id=DOID:3908"
            },
            "drugs": [
                {
                    "id": 12,
                    "name": "Crizotinib",
                    "ncit_id": "C74061",
                    "aliases": [
                        "Xalkori",
                        "PF-2341066",
                        "PF-02341066",
                        "MET Tyrosine Kinase Inhibitor PF-02341066",
                        "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                        "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine"
                    ]
                }
            ],
            "evidence_type": "Predictive",
            "evidence_direction": "Supports",
            "clinical_significance": "Sensitivity/Response",
            "fda_regulatory_approval": true,
            "status": "accepted"
        }
    ]
}